Hexarelin

Mechanism

Agonist at GHS-R1a driving growth hormone release, and binds CD36 in the heart, mediating its cardiovascular effects.

Reported effects

What sources associate with this compound. Reported categories, not outcomes we have graded — each would need its own citation and rung.

• Growth hormone release research
• Cardioprotection research
• Neuroprotection context

Half-life, storage & sport

Elimination half-life

71.9 min at 5 ug/kg, 61.4 min at 10 ug/kg, 57.0 min at 50 ug/kg (rat, SC) — study. Indian journal of pharmacology 2026; rats; figure reported by this paper from its reference 25, no cohort described.

Storage

Lyophilised: Stable at room temperature ~3 weeks; store desiccated below -18C. Reconstituted: 4C for 2-7 days; below -18C for future use; 0.1% HSA/BSA for long term; avoid freeze-thaw. — source. ProSpec technical datasheet. Supplier handling recommendation for research-grade lyophilate, not a per-compound stability study.

In sport (WADA 2026)

Prohibited, at all times — named S2.2.4 (GHRPs: examorelin (hexarelin)). the list

The half-life on file is 1.1 h, measured subcutaneously in rats. At the fastest schedule this record states — every 8 h — each dose has fallen to 0.57% of its own peak by the time the next is given. Nothing accumulates, and there is no loading phase to run. The record gives 14 to 21 times a week; the fastest is drawn.

The measurement is not human. It was made in rat, and small mammals clear peptides faster than people do — so this is the fastest plausible shape rather than the expected one.

The rise is not modelled and the axis is not a blood level. No absorption rate constant and no volume of distribution are on file, so each dose appears at full height the instant it is given, and the axis is percent of this compound's own peak.

Literature on file 6

• review or editorial
  Hexarelin: A multi-receptor peptide (2008, cited 1x) graded on: indexed as "Letter" - secondary literature, not a study — “Letter”
• review or editorial
  The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. graded on: indexed as "review-article" - secondary literature, not a study — “review-article”
• review or editorial
  Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives. graded on: indexed as "review-article" - secondary literature, not a study — “review-article”
• review or editorial
  Role of CD36 in central nervous system diseases. graded on: indexed as "review-article" - secondary literature, not a study — “review-article”
• animal in vivo
  Hexarelin promotes the survival of retinal ganglion cells after optic nerve transection. graded on: an animal model — read from the indexed abstract — “hamsters”
• in vitro
  Identification of alexamorelin consumption biomarkers using human hepatocyte incubations and high-resolution mass spectrometry. graded on: an in-vitro system — read from the indexed abstract — “in vitro”

What is circulated not evidence 3

Claims passed around in community guides and vendor copy, recorded because they circulate — not because they are true. Each is shown with the page it was read from and what this record actually holds. Checked 2026-08-24.

• unverified community data dose common nothing on file either way

  200 mcg twice daily, capped at 200 mcg per injection, is circulated as the standard dose, with 100 mcg once or twice daily as entry level.

  Standard research doses are 200 mcg twice daily.

  On the record No dosing record exists on file for hexarelin at all — the record holds only GH-release, cardioprotection and neuroprotection research context.

  Source 1 · Source 2

• unverified community data titration common nothing on file either way

  Hexarelin is circulated as desensitising faster than other GHRPs, so cycles are capped at 4-8 weeks with at least a 4-week washout, or rotation to another GHRP.

  Recommended cycles are 6 to 8 weeks on followed by 4 to 8 weeks off

  On the record The on-file human PK shows dose-dependent half-life figures only; no desensitisation time-course or cycling record exists.

  Source 1 · Source 2

• unverified community data stacking occasional nothing on file either way

  Rotating between hexarelin, ipamorelin and GHRP-2 in 4-8 week blocks is circulated as a way to keep GH response while receptors recover.

  4 weeks hexarelin, then 4-8 weeks ipamorelin or GHRP-2, then return

  On the record Nothing on file; no rotation or cross-tolerance record exists for any GHRP pair.

  Source 1

Identity

PubChem CID 6918297 computed 3D conformer

Skeletal formulathe canonical depiction

Drawn by PubChem from CID 6918297, the identifier on this record.

Molecular weight

887.0

Molecular formula

C47H58N12O6

CAS number

140703-51-1

PubChem CID

6918297

InChI key

RVWNMGKSNGWLOL-GIIHNPQRSA-N

Sequence

HXAWFK

SMILES

CC1=C(C2=CC=CC=C2N1)C[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@H](CC5=CC=CC=C5)C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CC6=CN=CN6)N

InChI

InChI=1S/C47H58N12O6/c1-27-34(33-15-7-9-17-37(33)54-27)23-41(58-44(62)35(49)22-31-25-51-26-53-31)45(63)55-28(2)43(61)57-40(21-30-24-52-36-16-8-6-14-32(30)36)47(65)59-39(20-29-12-4-3-5-13-29)46(64)56-38(42(50)60)18-10-11-19-48/h3-9,12-17,24-26,28,35,38-41,52,54H,10-11,18-23,48-49H2,1-2H3,(H2,50,60)(H,51,53)(H,55,63)(H,56,64)(H,57,61)(H,58,62)(H,59,65)/t28-,35-,38-,39+,40-,41+/m0/s1

Listed prices 100

What 64 shops we track listed for Hexarelin, read from their own public catalogues on 2026-09-14. We take no commission on these and they are not ranked by any payment — how vendors are scored.

Share this record